# Antifungals {#sec-antifungals}

Antifungal drugs occur in **three classes**:

* **Azoles**\
All have excellent oral bioavailability.
	* Generally fungicidal by inhibiting ergosterol synthesis in the cell wall\
	Fungistatic in some organism-dependent cases, notably aspergillus with voriconazole.
* **Echinocandins**\
All three agents are similar enough to be clinically interchangeable.
	* Inhibit β-glucan synthesis causing cell wall instability, which is:
		* Fungicidal for yeasts
		* Fungistatic for aspergillus
* **Polyenes**\
Essentially restricted to Amphotericin.
	* Fungicidal by binding to ergosterol

## Drugs

+------------------+--------------------------------------------------+-------------------------------------------------+
| Drug             | Fluconazole                                      | Voriconazole                                    |
+==================+==================================================+=================================================+
| Indications      | * Yeasts\                                        | * Invasive Aspergillosis                        |
|                  | Covers **most Candida** species.                 | * Fluconazole-resistant Candida                 |
|                  | * Excludes *C. glabrata* and *C. Krusei*         | * Endemic fungi\                                |
|                  |                                                  | Coccidiomycosis, histoplasmosis, blastomycosis. |
+------------------+--------------------------------------------------+-------------------------------------------------+
| Dosing           | * Systemic\                                      | * *Aspergillus*\                                |
|                  | 800mg IV load, 200mg IV BD                       | 6mg/kg IV load (BD), then 4mg/kg BD thereafter. |
|                  | * Esophageal\                                    |                                                 |
|                  | 200mg IV load, 50mg IV BD.                       |                                                 |
+------------------+--------------------------------------------------+-------------------------------------------------+
| Key pharmacology | * Renal elimination unchanged                    | * IV contraindicated if GFR <50mL/min\          |
|                  | * Dose ↓ 50% if GFR <50mL/min                    | PO dosing safe and unchanged.                   |
|                  | * Dose ↑ in CRRT\                                | * Dose ↓ 50% in hepatic dysfunction             |
|                  | Usual renal tubular reabsorption does not occur. | * Extensive CYP interactions                    |
|                  | * Extensive CYP interactions\                    |                                                 |
|                  | e.g. Tacrolimus, warfarin, phenytoin.            |                                                 |
+------------------+--------------------------------------------------+-------------------------------------------------+
| Toxicity         | * ↑ QTc                                          | * Neurotoxicity\                                |
|                  | * Hepatitis                                      | Delirium, myoclonus.                            |
|                  |                                                  | * Nephrotoxicity\                               |
|                  |                                                  | IV only.                                        |
|                  |                                                  | * ↑ QTc                                         |
|                  |                                                  | * Psychosis                                     |
+------------------+--------------------------------------------------+-------------------------------------------------+
| Other            | * No evidence for surgical prophylaxis           |                                                 |
+------------------+--------------------------------------------------+-------------------------------------------------+

: Comparison of Azoles


+------------------+-----------------------------------------------------------------------------------------------+--------------------------------------------------------------+
| Drug             | Echinocandins                                                                                 | Liposomal Amphotericin                                       |
+==================+===============================================================================================+==============================================================+
| Indications      | * Candida\                                                                                    | * *Cryptococcus Neoformans*                                  |
|                  | Resistance is rare; may occur with *C. parapsilosis*, *C. glabrata*, and *C. guilliermondii*. | * Dimorphic fungi\                                           |
|                  | * Aspergillus\                                                                                | Change between yeast and mould form.                         |
|                  | Not as monotherapy; synergistic with voriconazole.                                            | * Moulds                                                     |
|                  |                                                                                               | * Otherwise resistant fungi                                  |
+------------------+-----------------------------------------------------------------------------------------------+--------------------------------------------------------------+
| Dosing           | * Caspofungin\                                                                                | * 3-5mg/kg IV Q24H                                           |
|                  | 70mg IV load, then 50mg IV daily.                                                             |                                                              |
|                  | * Anidulafungin\                                                                              |                                                              |
|                  | 200mg IV load, then 100mg IV daily.                                                           |                                                              |
|                  | * Micafungin\                                                                                 |                                                              |
|                  | 100-150mg IV daily.                                                                           |                                                              |
+------------------+-----------------------------------------------------------------------------------------------+--------------------------------------------------------------+
| Key pharmacology | * Very highly protein bound                                                                   | * No hepatic impact\                                         |
|                  | * No renal or hepatic dose reduction required                                                 | Major role in treating fungal infections in hepatic failure. |
|                  |                                                                                               | * Contraindicated in renal failure                           |
|                  |                                                                                               |                                                              |
+------------------+-----------------------------------------------------------------------------------------------+--------------------------------------------------------------+
| Toxicity         | * Avoid in acute hepatic failure\                                                             | * Infusion reactions\                                        |
|                  | Results in deranged LFTs, confounding monitoring.                                             | Atopic/immune symptoms.                                      |
|                  |                                                                                               | * AKI                                                        |
|                  |                                                                                               | * RTA                                                        |
+------------------+-----------------------------------------------------------------------------------------------+--------------------------------------------------------------+

: Comparison of Other Antifungals

:::column-margin
Liposomal amphotericin has replaced other more toxic amphotericin preparations.
::: 

---

## References

1. Bersten, A. D., & Handy, J. M. (2018). Oh’s Intensive Care Manual. Elsevier Gezondheidszorg.